Based on the Tandem Diabetes Care Inc stock forecast from 12 analysts, the average analyst target price for Tandem Diabetes Care Inc is USD 48.05 over the next 12 months. Tandem Diabetes Care Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Tandem Diabetes Care Inc is Bearish, which is based on 2 positive signals and 6 negative signals. At the last closing, Tandem Diabetes Care Inc’s stock price was USD 19.11. Tandem Diabetes Care Inc’s stock price has changed by -43.11% over the past week, -47.91% over the past month and -29.50% over the last year.
No recent analyst target price found for Tandem Diabetes Care Inc
No recent average analyst rating found for Tandem Diabetes Care Inc
Company Overview Tandem Diabetes Care Inc
Tandem Diabetes Care, Inc., a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system. It also sells single-use products, including cartridges for storing and delivering insulin, and infusion sets that connect the insulin pump to the user's body. In addition, the company offers Tandem Device Updater used to update the pump software from a personal computer; Tandem Source, a web-based data management platform, which provides a visual way to display diabetes therapy management data from the pumps, integrated CGMs, and supported blood glucose meters; and Sugarmate, a mobile app used to help people visualize diabetes therapy data. It has collaboration agreement with the University of Virginia Center for Diabetes Technology for research and development of fully automated closed-loop insulin delivery systems. The company was formerly known as Phluid Inc. and changed its name to Tandem Diabetes Care, Inc. in January 2008. Tandem Diabetes Care, Inc. was incorporated in 2006 and is headquartered in San Diego, California. Read Less
Tandem Diabetes Care, Inc., a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for ...Read More
Frequently Asked Questions About Tandem Diabetes Care Inc (TNDM) Stock
Based on ratings from 12 analysts Tandem Diabetes Care Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Bearish. The stock has 12 buy, sell and 8 hold ratings.
Unfortunately we do not have enough data on TNDM's stock to indicate if its a good dividend stock.
Based on targets from 12 analysts, the average taret price for TNDM is USD 48.05 over the next 12 months. The maximum analyst target price is USD 75 while the minimum anlayst target price is USD 22.
TNDM stock's Price/Earning ratio is 495.13.
Our analysis grades TNDM stock's Price / Earning ratio at F. This means that TNDM stock's Price/Earning ratio is above 97% of the stocks in the Medical Devices sector in the NSD exchange.
Based on this TNDM may be a overvalued for its sector.
The last closing price of TNDM's stock was USD 19.11.
The most recent market capitalization for TNDM is USD 2.11B.
Based on targets from 12 analysts, the average taret price for TNDM is projected at USD 48.05 over the next 12 months.
This means that TNDM's stock price may go up by +151.44% over the next 12 months.
We can't find any ETFs which contains Tandem Diabetes Care Inc's stock.
As per our most recent records Tandem Diabetes Care Inc has 2,400 Employees.
Tandem Diabetes Care Inc's registered address is 12400 High Bluff Drive, San Diego, CA, United States, 92130.
You can get more information about it from Tandem Diabetes Care Inc's website at https://www.tandemdiabetes.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
Superior Revenue Growth
This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
Overpriced compared to earnings
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Highly leveraged
The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.
Frequently Asked Questions About Tandem Diabetes Care Inc (TNDM) Stock
Based on ratings from 12 analysts Tandem Diabetes Care Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Bearish. The stock has 12 buy, sell and 8 hold ratings.
Unfortunately we do not have enough data on TNDM's stock to indicate if its a good dividend stock.
Based on targets from 12 analysts, the average taret price for TNDM is USD 48.05 over the next 12 months. The maximum analyst target price is USD 75 while the minimum anlayst target price is USD 22.
TNDM stock's Price/Earning ratio is 495.13.
Our analysis grades TNDM stock's Price / Earning ratio at F. This means that TNDM stock's Price/Earning ratio is above 97% of the stocks in the Medical Devices sector in the NSD exchange.
Based on this TNDM may be a overvalued for its sector.
The last closing price of TNDM's stock was USD 19.11.
The most recent market capitalization for TNDM is USD 2.11B.
Based on targets from 12 analysts, the average taret price for TNDM is projected at USD 48.05 over the next 12 months.
This means that TNDM's stock price may go up by +151.44% over the next 12 months.
We can't find any ETFs which contains Tandem Diabetes Care Inc's stock.
As per our most recent records Tandem Diabetes Care Inc has 2,400 Employees.
Tandem Diabetes Care Inc's registered address is 12400 High Bluff Drive, San Diego, CA, United States, 92130.
You can get more information about it from Tandem Diabetes Care Inc's website at https://www.tandemdiabetes.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for TNDM !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
